Holen Sie sich die Stockscreener-App
6.26
1.13%
0.07
Handel nachbörslich:
6.26
Schlusskurs vom Vortag:
$6.19
Offen:
$6.23
24-Stunden-Volumen:
967.65K
Relative Volume:
0.54
Marktkapitalisierung:
$1.08B
Einnahmen:
$291.85M
Nettoeinkommen (Verlust:
$554.00K
KGV:
-823.68
EPS:
-0.0076
Netto-Cashflow:
$27.93M
1W Leistung:
+5.74%
1M Leistung:
+3.47%
6M Leistung:
-12.81%
1J Leistung:
+29.61%
1-Tages-Spanne:
$6.145
$6.28
1-Wochen-Bereich:
$5.91
$6.435
52-Wochen-Spanne:
$4.30
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.26 | 1.07B | 291.85M | 554.00K | 27.93M | -0.0076 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
XERS Technical Analysis | Trend, Signals & Chart Patterns | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
What Xeris Biopharma Holdings (XERS)'s Profit Return and Higher 2026 Guidance Means For Shareholders - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Stock Price, News, Quote & History - Yahoo Finance
Xeris Biopharma Quality Draws Market Attention Through Growth Signals - Kalkine Media
Xeris Biopharma Holdings, Inc. (XERS) Latest Stock News & Headlines - Yahoo Finance
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings - simplywall.st
Vanguard Group Inc. Buys 1,358,760 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
TradingKey - TradingKey
Xeris Biopharma (XERS) Stock Price, News & Analysis $XERS - MarketBeat
Xeris Biopharma Q3 EPS Forecast Decreased by HC Wainwright - MarketBeat
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike - Sahm
Xeris forecasts $380M-$390M 2026 revenue as Recorlev commercial expansion ramps in H2 - MSN
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit - Yahoo Finance
Number of shareholders of Xeris Biopharma Holdings, Inc. – DUS:2B30 - TradingView
Xeris Biopharma Q1 Earnings Call Highlights - MarketBeat
Q1 2026 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Xeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 ProfitabilityWhat's Changed - Yahoo Finance
Xeris Biopharma Reports First Quarter 2026 Financial Results - BioSpace
Xeris (XERS) Q1 2026 Earnings Call Transcript - The Globe and Mail
Rekorlev-driven revenue lifts Xeris Biopharma (XERS) to Q1 2026 profitability - Stock Titan
Earnings call transcript: Xeris Biopharma Q1 2026 reports solid growth By Investing.com - Investing.com South Africa
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XERS: Q1 revenue jumped 43% year-over-year, prompting a raised full-year outlook to $380–$390 million - TradingView
Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge - ChartMill
Earnings Flash (XERS) Xeris Biopharma Holdings Posts Q1 EPS $0.01, vs. FactSet Est of $0.01 Loss per Share - marketscreener.com
Xeris Biopharma: Q1 Earnings Snapshot - Barchart.com
Xeris Biopharma (XERS) surges with 38% Q1 revenue growth and profit - Stock Titan
Xeris Pharmaceuticals Q1 2026 earnings preview - MSN
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biop - GuruFocus
Insider Sell Alert: Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Xeris Biopharma’s chief legal officer sells $103,805 in stock By Investing.com - Investing.com Canada
Xeris Biopharma’s chief legal officer sells $103,805 in stock - Investing.com
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan
Xeris Biopharma (XERS) to Release Earnings on Thursday - MarketBeat
Xeris Biopharma Reports Third Quarter 2024 Financial Results - Quantisnow
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Xeris Biopharma expects full-year 2025 revenue above estimates - MSN
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 - BioSpace
Xeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Xeris Biopharma (NASDAQ: XERS) details 2026 votes on pay, board, auditor - Stock Titan
Xeris (XERS) Year-Ahead Outlook | Q4 2025: EPS Exceeds ExpectationsDark Pool - Cổng thông tin điện tử Tỉnh Sơn La
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks |
Apr 01 '26 |
Sale |
5.99 |
16,667 |
99,859 |
1,209,840 |
| Brady James Aloysius | Director |
Mar 30 '26 |
Sale |
5.54 |
10,834 |
60,036 |
89,166 |
5.02%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):